The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living individuals as well as samples from those recently deceased who are suspected to have died from Ebola. The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test that the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. “Today’s marketing authorization provides another important tool in the effort to fight Ebola,” said FDA Acting Commissioner Ned Sharpless, M.D. “…This marketing authorization may provide additional assurances to health care professionals seeking to use these types of rapid diagnostics. The ability to use this test to promptly make a presumptive Ebola diagnosis could help providers to more quickly isolate patients and begin treatments that can be potentially life-saving.”

Related News Articles

Headline
An estimated one in five people in the United States had a sexually transmitted infection at some point in 2018, with almost half of new infections in those…
Headline
The Centers for Disease Control and Prevention today joined the global public health community in marking the end of the Ebola outbreak in the Democratic…
Headline
The Food and Drug Administration Oct. 14 approved Inmazeb for treating Zaire ebolavirus infection in adult and pediatric patients. The drug is a mixture…
Headline
The Department of Health and Human Services and the Steven and Alexandra Cohen Foundation Oct. 10 announced the LymeX Innovation Accelerator, a $25 million,…
Headline
The Democratic Republic of the Congo has reported 100 confirmed or probable Ebola cases and 43 deaths in Equateur Province since June 1, the World Health…
Headline
The Centers for Disease Control and Prevention yesterday joined the World Health Organization to declare the end of the Ebola Virus Disease outbreak in the…